Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 7)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 10.06.24 20:06:07 von
neuester Beitrag 10.06.24 20:06:07 von
Beiträge: 23.635
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 1.388
Gesamt: 1.276.904
Gesamt: 1.276.904
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVAX
14,870
EUR
-11,56 %
-1,944 EUR
Letzter Kurs 22:26:41 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
19:00 Uhr · Felix Haupt Anzeige |
07.06.24 · LYNX Analysen Anzeige |
23.05.24 · wallstreetONLINE Redaktion |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 14.05.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 27,50 | +32,21 | |
| 0,9510 | +28,08 | |
| 1,3100 | +21,30 | |
| 0,7401 | +20,54 | |
| 3,9300 | +18,37 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,8150 | -25,78 | |
| 3,4700 | -33,27 | |
| 1,1600 | -35,20 | |
| 0,5541 | -40,93 | |
| 0,9500 | -43,11 |
Beitrag zu dieser Diskussion schreiben
Feedback
Novavax, With A 369% Gain, Reverses Bullish Gains After Key FDA Move
ALLISON GATLIN04:15 PM ET 06/06/2024
Novavax (NVAX) stock zipped higher Thursday — and then gave it all up — after the Food and Drug Administration set a potential approval date for its Covid vaccine in April.
In a filing with the Securities and Exchange Commission, Novavax said the FDA said it completed its filing review of the final portion of its request for approval. The agency is set to make its decision in April 2025.
The news initially sent Novavax stock as high as 13%. But Novavax shares closed down 6.8% at 19.56.
On Wednesday, Novavax said it plans to launch an updated booster to target the JN.1 variant, in line with the FDA Vaccines and Related Biological Products Advisory Committee's recommendation. Pfizer (PFE) and Moderna (MRNA) are also planning to prepare JN.1-focused boosters.
Novavax stock has been on a tear recently, surging 369% from dollar-stock status on May 9 to the closing price of 20.97 on Wednesday. Shares now have a perfect IBD Digital Relative Strength Rating of 99 and opened at their highest point since November 2022. The RS Rating is a 1-99 measure of a stock's 12-month performance.
Novavax Stock: Reversing Its Fortunes
Novavax's Covid vaccine has faced a number of setbacks over the years. The vaccine is based on protein technology, which is appealing to people hesitant to use the newer messenger RNA-based shots from Pfizer with partner BioNTech (BNTX) and Moderna.
But the Novavax Covid vaccine has never been officially approved. Instead, the company has racked up sales under an emergency use authorization. Last September, the FDA approved updated boosters from Pfizer and Moderna, but didn't authorize Novavax's shot until October.
Recent news, though, has set Novavax stock on a sprint. Shares skyrocketed more than 125% on May 10 after the company inked a licensing deal with Sanofi (SNY) for its Covid vaccine. Sanofi will pay Novavax $500 million up front. Milestone, regulatory and other payments could add $700 million.
The companies also agreed to co-develop a Covid/flu vaccine. Sanofi will co-commercialize it worldwide.
Since then. Novavax stock has continued climbing. Shares easily retook their 50-day and 200-day moving averages, MarketSurge shows. Notably, Novavax shares now have an improved Composite Rating of 89, putting their technical and fundamental performance in the leading 11% of all stocks.
Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Find The Best Long-Term Investments With IBD Long-Term Leaders
Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader
Learn How To Time The Market With IBD's ETF Market Strategy
RELATED NEWS
Moderna stock
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
5/31/2024 The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
Is Moderna Stock A Buy As The U.S. Government Mulls Its Bird Flu Vaccine?
The U.S. Is Close To Bankrolling Moderna's Bird Flu Vaccine As Third Dairy Worker Tests Positive
Option Trade On Volatile Moderna Stock Could Return 28% By Mid-July
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Is Novavax Stock A Buy After Nearly Tripling On $1.3 Billion Sanofi Deal?
Stocks To Watch: Moderna Sees Relative Strength Rating Rise To 92
Moderna Tumbles After The FDA Throws A Curveball On Its Second Product
Biotech Rockets 125% On Sanofi Covid Vaccine Agreement
https://www.investors.com/news/technology/novavax-stock-fda-…
ALLISON GATLIN04:15 PM ET 06/06/2024
Novavax (NVAX) stock zipped higher Thursday — and then gave it all up — after the Food and Drug Administration set a potential approval date for its Covid vaccine in April.
In a filing with the Securities and Exchange Commission, Novavax said the FDA said it completed its filing review of the final portion of its request for approval. The agency is set to make its decision in April 2025.
The news initially sent Novavax stock as high as 13%. But Novavax shares closed down 6.8% at 19.56.
On Wednesday, Novavax said it plans to launch an updated booster to target the JN.1 variant, in line with the FDA Vaccines and Related Biological Products Advisory Committee's recommendation. Pfizer (PFE) and Moderna (MRNA) are also planning to prepare JN.1-focused boosters.
Novavax stock has been on a tear recently, surging 369% from dollar-stock status on May 9 to the closing price of 20.97 on Wednesday. Shares now have a perfect IBD Digital Relative Strength Rating of 99 and opened at their highest point since November 2022. The RS Rating is a 1-99 measure of a stock's 12-month performance.
Novavax Stock: Reversing Its Fortunes
Novavax's Covid vaccine has faced a number of setbacks over the years. The vaccine is based on protein technology, which is appealing to people hesitant to use the newer messenger RNA-based shots from Pfizer with partner BioNTech (BNTX) and Moderna.
But the Novavax Covid vaccine has never been officially approved. Instead, the company has racked up sales under an emergency use authorization. Last September, the FDA approved updated boosters from Pfizer and Moderna, but didn't authorize Novavax's shot until October.
Recent news, though, has set Novavax stock on a sprint. Shares skyrocketed more than 125% on May 10 after the company inked a licensing deal with Sanofi (SNY) for its Covid vaccine. Sanofi will pay Novavax $500 million up front. Milestone, regulatory and other payments could add $700 million.
The companies also agreed to co-develop a Covid/flu vaccine. Sanofi will co-commercialize it worldwide.
Since then. Novavax stock has continued climbing. Shares easily retook their 50-day and 200-day moving averages, MarketSurge shows. Notably, Novavax shares now have an improved Composite Rating of 89, putting their technical and fundamental performance in the leading 11% of all stocks.
Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Find The Best Long-Term Investments With IBD Long-Term Leaders
Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader
Learn How To Time The Market With IBD's ETF Market Strategy
RELATED NEWS
Moderna stock
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
5/31/2024 The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
Is Moderna Stock A Buy As The U.S. Government Mulls Its Bird Flu Vaccine?
The U.S. Is Close To Bankrolling Moderna's Bird Flu Vaccine As Third Dairy Worker Tests Positive
Option Trade On Volatile Moderna Stock Could Return 28% By Mid-July
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Is Novavax Stock A Buy After Nearly Tripling On $1.3 Billion Sanofi Deal?
Stocks To Watch: Moderna Sees Relative Strength Rating Rise To 92
Moderna Tumbles After The FDA Throws A Curveball On Its Second Product
Biotech Rockets 125% On Sanofi Covid Vaccine Agreement
https://www.investors.com/news/technology/novavax-stock-fda-…
Investierte die richtig Geld verdienen, haben nicht das Verlangen noch die Zeit hier zu Posen, oder besser gesagt zu prollen
Antwort auf Beitrag Nr.: 75.906.033 von Another-earth am 07.06.24 08:24:10Ich sehe doch meinen Ausführungskurs
Antwort auf Beitrag Nr.: 75.906.006 von rexe05351 am 07.06.24 08:20:59Du meinst ich bin dumm oder? ICh habe über 2 Jahre DCA betrieben und bin auch schon mit den Aktien im Plus.
moin, nicht immer alles glauben was geschrieben steht. Wer mit Zertifikaten handelt , weiß auch dass mit unterschreiten einer Schwelle, die Emitenten zwar den Verkauf zulassen aber keine Scheine mehr anbieten . Ich habe diverse bei Palantir und NVidia gehabt die ich beim Zurückgang der Aktie aufstocken wollte ,, ging aber nicht und das sind oft Scheine die um über 99 % gefallen sind , eine lange Laufzeit haben,,, Grund der Emitent ist nicht bescheuert, wenn da mal einer ein paar hunder Euro setzt und nachher um die 100 000 abzieht, das reicht auch schon aus. Von ganz kurzen Laufzeiten schreibe ich aber nicht, denn die fasse ich nicht an, da die Warscheinlichkeit des Totalverlustes recht hoch ist. Dann gibt es da noch scheine z.B. wieder Pal oder Supermicro und und und , die haben tw mehrere hunder % spread , die kosten dann nicht 0,05 Euro, sondern 1 Euro im Einkauf und man erhält bei VK dann die 0,05
sh. auch Obtionsscheinrechner bei ONVISTA
sh. auch Obtionsscheinrechner bei ONVISTA
Trading Spotlight
Deckel drauf bei 18,39€
wie angenagelt
Antwort auf Beitrag Nr.: 75.905.967 von BTC123 am 07.06.24 08:15:41Deine Aktien musst du Genie auch noch bis 95€ halten.. dein Einstandskurs wird nicht weit darunter liegen
Antwort auf Beitrag Nr.: 75.903.741 von sokol22 am 06.06.24 19:15:22Ich habe nie behauptet dass ich raus bin. Meine Aktien hab ich alle noch. Ich hab lediglich meinen OS verkauft
Man könnte es zumindest merkwürdig finden, wenn man von 60$ Kursen spricht, vom Gamma Squeeze, alle Kritiker bezahlt seien, man auf diese nicht hören soll, man unbeirrt weiter machen soll, somit zum Kaufen anregt und selbst bei 25$ aussteigt, während es nach unten fällt.
Antwort auf Beitrag Nr.: 75.904.584 von BTC123 am 06.06.24 21:12:09D.h. du findest es ok - als Oberpusher - an dem Tag wo der Kurs von 27$ auf 20$ runter rauscht - zu verkünden: man habe eine Viertelmillion durch Verkaufen verdient?
Also ich bin ja fein damit. Glückwunsch! Alles richtig gemacht! Als kleiner Pusher würde ich mich bissle veräppelt fühlen.
Also ich bin ja fein damit. Glückwunsch! Alles richtig gemacht! Als kleiner Pusher würde ich mich bissle veräppelt fühlen.
Durchsuchen
23.05.24 · wallstreetONLINE Redaktion · Pfizer |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 14.05.24 · wallstreetONLINE Redaktion · Sanofi |
10.05.24 · dpa-AFX · McDonald's |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Enel |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Sanofi |
